Adem Emrah COGUPLUGİL, Alper GÜNDOĞAN, Nesrin ÖCAL, İbrahim YILDIRIM, Seyfettin GÜMÜŞ, Turgay EBİLOĞLU, Zafer DEMİRER, ENGİN KAYA, Giray ERGİN

Interstitial pneumonia: A rare complication after intravesical Mitomycin-C treatment for bladder tumor

Transüretral mesane tümörü rezeksiyonu sonrası mesane içi Mitomycin-C instilasyonu başlanan 66 yaşında bir erkek hastada interstisyel pnömoni gelişti. Hastaya haftalık 40 mg mesane içi Mitomycin-C uygulanmıştı ve üçüncü uygulamadan 4 gün sonra hasta acil servise ilerleyici dispne şikayeti ile başvurdu. Çekilen yüksek çözünürlüklü toraks tomografisinde akciğerin sağ üst ve her iki alt loblarında buzlu cam görüntüsü, iki taraflı plevral efüzyon ve interlobuler septal kalınlaşma görüntülendi. Akciğer infeksiyonu ve kollajen vasküler hastalıklar dışlandı. İnterstisyel pnömoni öntanısıyla Mitomycin-C tedavisinin bırakılıp prednizolon tedavisi başlanmasıyla semptomatik ve radyolojik iyileşme sağlandı. Mesane içi Mitomycin-C interstisyel pnömoni gibi nadir sistemik yan etkilere neden olabilir

İnterstisyel pnömoni: Mesane tümörü için uygulanan mesane içi Mitomycin-C tedavisinden sonra gelişen nadir bir komplikasyon

Sixty six years-old male patient, who underwent transurethral resection of bladder tumor and consequent intravesical Mitomycin-C chemotherapy, developed interstitial pneumonia. Forty mg intravesical Mitomycin-C was instillated weekly. Four days after the third instillation, the patient presented to emergency service with the complaint of progressive dyspnea. High resolution thorax tomography demonstrated ground glass opacity in the right upper and bilateral lower lobes, bilateral pleural effusion and interlobular septal thickening. Infection and collagen vascular disease were excluded. Symptomatic and radiological improvement achieved with discontinuation of intravesical Mitomycin-C and initiation of prednisolone treatment. Intravesical Mitomycin-C may cause rare systemic side effects like interstitial pneumonia

PDF

___

1. Castro M, Veeder MH, Mailliard JA, Tazelaar HD, Jett JR. A prospective study of pulmonary function in patients receiving mitomycin. Chest 1996;109:939-44.

2. Shapiro O, Jones K, Wang C, Landas S, Haas GP. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection. Can J Urol 2006;13:3317-20.

3. Verweij J, van Zanten T, Souren T, Golding R, Pinedo HM. Prospective study on the dose relationship of mitomycin Cinduced interstitial pneumonitis. Cancer 1987; 60:756-61.

4. Wada H, Nakano Y, Yamada H, Saiga T, Yamanaka A, Sakai N. Intravesical Mitomycin-C Induced Interstitial Pneumonia. Respiration 2010;80:256–259.

5. Orwoll ES, Kiessling PJ, Patterson JR. Interstitial pneumonia from mitomycin. Ann Intern Med 1978 ;89:352-5.

6. Wilhelms E, Criée CP, Neubauer H, Neuhaus KL. Lung parenchyma disease following instillation of mitomycin C in the bladder. Dtsch Med Wochenschr 1986;111:1564-6.

7. Neubauer H, Blech M, Wilhelms E, Crieé CP, Neuhaus KL, Truss F. Pulmonary fibrosis following instillation of mitomycin C in the urinary bladder. Urologe A 1987;26:41-3.

8. Perros F, Günther S, Ranchoux B, et al. MitomycinInduced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. Circulation 2015;132:834-47.

9. Yoon JM, Rao U, Vassilopoulos PP, Ledesma E, Mittelman A. Interstitial pneumonitis associated with mitomycin C and DTIC: a case report. Med Pediatr Oncol 1981;9:61-7.

10. Okuno, SH, Frytak S. Mitomycin Lung Toxicity: Acute and Chronic Phases. Am J Clin Oncol 1997; 20: 282–284.

11. Linette DC, McGee KH, McFarland JA. Mitomycin-induced pulmonary toxicity: case report and review of the literature. Ann Pharmacother 1992; 26:481-4.